Merck Sharp + Dohme Corp.

Elexopharm Gmbh

Universitaet Des Saarlandes Campus Saarbruecken

Qingzhong Hu

Rolf Wolfgang Hartmann

Amjad Ali

Michael Man-Chu Lo

Ralf Heim

Lina Yin

Christina Zimmer

Edward Metzger

Yusheng Xiong

Timothy J Henderson

Bheemashankar A Kulkarni

Clare London

Scott B Hoyt

Jerry Andrew Taylor

Swapan Kumar Samanta

Rohit Saxena

Emmanuel Bey

Whitney Lane Petrilli

Carsten A Vock

Ulrike Hille

Bey; Emmanuel

Michael Lo

This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Indoline compounds as aldosterone synthase inhibitors

This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase. 

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

Aldosterone synthase inhibitors

Growing community of inventors

Saarbrucken, Germany

Qingzhong Hu